Nature Communications (Mar 2023)
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
- Ainhoa Madariaga,
- Swati Garg,
- Nairi Tchrakian,
- Neesha C. Dhani,
- Waldo Jimenez,
- Stephen Welch,
- Helen MacKay,
- Josee-Lyne Ethier,
- Lucy Gilbert,
- Xuan Li,
- Angela Rodriguez,
- Lucy Chan,
- Valerie Bowering,
- Blaise Clarke,
- Tong Zhang,
- Ian King,
- Gregory Downs,
- Tracy Stockley,
- Lisa Wang,
- Smitha Udagani,
- Amit M. Oza,
- Stephanie Lheureux
Affiliations
- Ainhoa Madariaga
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Swati Garg
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Nairi Tchrakian
- University of Toronto
- Neesha C. Dhani
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Waldo Jimenez
- Division of Gynecologic Oncology, Juravinski Cancer Centre
- Stephen Welch
- Division of Medical Oncology and Hematology, London Health Sciences Center, London Regional Cancer Program
- Helen MacKay
- Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre
- Josee-Lyne Ethier
- Division of Medical Oncology and Hematology, Kingston Health Sciences Cancer Centre
- Lucy Gilbert
- Division of Gynecologic Oncology, McGill University Health Centre, Royal Victoria Hospital
- Xuan Li
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network
- Angela Rodriguez
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Lucy Chan
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Valerie Bowering
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Blaise Clarke
- University of Toronto
- Tong Zhang
- Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network
- Ian King
- Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network
- Gregory Downs
- Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network
- Tracy Stockley
- Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network
- Lisa Wang
- University of Toronto
- Smitha Udagani
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Amit M. Oza
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- Stephanie Lheureux
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
- DOI
- https://doi.org/10.1038/s41467-023-37084-w
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 11
Abstract
Treatment options in patients with recurrent endometrial carcinoma (EC) are limited and response rates to chemotherapy are poor. Here the authors report the results of a phase II trial of niraparib (PARP inhibitor) monotherapy or in combination with dostarlimab (anti-PD1) in recurrent EC.
